Investors & Media

We are driven to develop meaningful therapies for patients while creating value for stockholders.

Investors & Media

Corporate Profile

We are a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing innovative medicines for people with serious diseases of the central nervous system (CNS).

Press Releases

Mar 27, 2023

Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases

Mar 22, 2023

Cyclerion Reports Corporate Update and Full Year 2022 Financial Results

Nov 22, 2022

Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company

Oct 06, 2022

Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy

view all

Stock Quote

Change
Volume
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Corporate Presentation July 2022
Top